Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gout drug shows promise for diabetic kidney protection in small trial

NCT ID NCT07177898

Disease control Sponsor: Narowal Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study tested whether adding allopurinol (a gout medication) to standard lisinopril treatment could better protect kidneys in people with type 2 diabetes. 80 patients with normal uric acid levels were split into two groups: one received both drugs, the other lisinopril alone. Researchers tracked kidney function over a year to see if urine albumin levels rose, a sign of kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
allopurinol and lisinopril
What this could lead to
If adding allopurinol works, it could offer a simple, low-cost way to help protect kidneys in people with type 2 diabetes.
What could go wrong
This is a small, single-center study with only 80 participants. Results may not apply to everyone, and the benefit might be small or not confirmed in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

May 2023

Finished

Nov 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with type 2 diabetes mellitus on oral hypoglycemic agents, serum creatinine levels less than 1.1 mg/dL, and serum uric acid levels between 5.5-6.5 mg/dL for males and 5-6 mg/dL for females Exclusion Criteria: * patients with tumor lysis syndrome, chronic kidney disease from other causes (e.g., hypertension, glomerulonephritis, polycystic kidney disease, or hydronephrosis), those on medications that could cause hyperuricemia (such as thiazide diuretics) or those on drugs that may induce proteinuria (e.g., NSAIDs, cyclosporine, penicillamine, or gold). Patients with uric acid levels exceeding 7 mg/dL were also excluded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic kidney disease (DKD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic kidney disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic kidney disease (DKD)

Contacts and locations

Locations

  • King Edward Medical University

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.